Who is sponsoring NCT04174625?

NCT04174625 is sponsored by Applied Science Private University.

What drugs are being tested in NCT04174625?

Interventions in NCT04174625: Dietary Supplement: Omega3-FA.

What condition does NCT04174625 study?

NCT04174625 studies 25-hydroxyvitamin D Levels.

Is NCT04174625 still recruiting?

NCT04174625 is currently completed. Last updated 24 February 2022.

Last reviewed 2022-02-24 · How we verify

NCT04174625: n-3FAon25OHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Omega 3 on 25 Hydroxyvitamin D

Completed NA Last updated 24 February 2022

What this trial tests

NA trial testing Dietary Supplement: Omega3-FA in 25-hydroxyvitamin D Levels in 80 participants. Completed in 15 December 2021.

Timeline

25 November 2020

Primary endpoint
17 July 2021

15 December 2021

Quick facts

Lead sponsor	Applied Science Private University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	80
Start date	25 November 2020
Primary completion	17 July 2021
Estimated completion	15 December 2021
Sites	1 location across Jordan

Drugs / interventions tested

Dietary Supplement: Omega3-FA

Conditions studied

25-hydroxyvitamin D Levels — all drugs for 25-hydroxyvitamin D Levels →

Sponsor

Applied Science Private University

Who can join

Adults 22 to 66, any sex, with 25-hydroxyvitamin D Levels. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effect of omega 3 fatty acid on serum 25-hydroxyvitamin D levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Applied Science Private University trials

Trials by the same sponsor.

NCT07520942 — TECAR and ESWT in Obesity-Related Lower Limb Lymphedema · NA · completed
NCT06346990 — The Effect of Listening to Holy Quran Recital on the Incidence of Delirium Post-CABG · NA · not yet recruiting
NCT04658433 — The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease an · NA · completed
NCT04682626 — Effect of Weekly High-dose Vitamin D3 Supplementation on the Association Between Circulatory FGF-23 and A1c Levels · NA · completed
NCT04476745 — The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04174625 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Applied Science Private University
Last refreshed: 24 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04174625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing